Website beoordeling agenusbio.com
Agenus: Better immunotherapies
Gegenereerd op Maart 28 2026 02:34 AM
Oude statistieken? UPDATE !
De score is 54/100
SEO Content
Title
Agenus: Better immunotherapies
Lengte : 30
Perfect, uw title tag bevat tussen de 10 en 70 karakters.
Description
Activating the Power of the Immune System to Defeat Cancer
Lengte : 58
Let op, uw meta description zou tussen de 70 en 160 karakters (spaces included) moeten bevatten.
Keywords
Erg slecht. We hebben geen meta keywords gevonden in uw website. Gebruik deze gratis online meta tags generator om keywords te genereren.
Og Meta Properties
Goed, uw page maakt gebruik van Og Properties.
| Property | Content |
|---|---|
| type | website |
Headings
| H1 | H2 | H3 | H4 | H5 | H6 |
| 2 | 24 | 65 | 0 | 0 | 0 |
- [H1] Using Your Immune System to Defeat Cancer
- [H1] Using Your Immune System to Defeat Cancer
- [H2] Agenus Reports 2025 Results; BOT+BAL Advances to Phase 3 and Early Access Programs Expand Globally with Initial Revenues Recognized
- [H2] Agenus Reports 2025 Results; BOT+BAL Advances to Phase 3 and Early Access Programs Expand Globally with Initial Revenues Recognized
- [H2] Agenus Reports 2025 Results; BOT+BAL Advances to Phase 3 and Early Access Programs Expand Globally with Initial Revenues Recognized
- [H2] Agenus Reports 2025 Results; BOT+BAL Advances to Phase 3 and Early Access Programs Expand Globally with Initial Revenues Recognized
- [H2] Agenus Reports 2025 Results; BOT+BAL Advances to Phase 3 and Early Access Programs Expand Globally with Initial Revenues Recognized
- [H2] Agenus Reports 2025 Results; BOT+BAL Advances to Phase 3 and Early Access Programs Expand Globally with Initial Revenues Recognized
- [H2] Agenus Reports 2025 Results; BOT+BAL Advances to Phase 3 and Early Access Programs Expand Globally with Initial Revenues Recognized
- [H2] Agenus Reports 2025 Results; BOT+BAL Advances to Phase 3 and Early Access Programs Expand Globally with Initial Revenues Recognized
- [H2] Agenus Reports 2025 Results; BOT+BAL Advances to Phase 3 and Early Access Programs Expand Globally with Initial Revenues Recognized
- [H2] Agenus Reports 2025 Results; BOT+BAL Advances to Phase 3 and Early Access Programs Expand Globally with Initial Revenues Recognized
- [H2] Agenus Announces Upcoming AACR 2026 Presentation Evaluating Botensilimab Plus Balstilimab in First-Line MSS Metastatic Colorectal Cancer
- [H2] Agenus Reports 2025 Results; BOT+BAL Advances to Phase 3 and Early Access Programs Expand Globally with Initial Revenues Recognized
- [H2] Agenus Expands Medical Affairs Infrastructure to Support Increasing Physician Requests for Authorized Access to Botensilimab Plus Balstilimab
- [H2] Agenus Announces Upcoming AACR 2026 Presentation Evaluating Botensilimab Plus Balstilimab in First-Line MSS Metastatic Colorectal Cancer
- [H2] Innovative Immunotherapies
- [H2] Learn how our science is changing what’s possible
- [H2] Stage III MSS Colorectal Cancer
- [H2] Merkel Cell Carcinoma
- [H2] Undifferentiated Pleomorphic Sarcoma
- [H2] Bringing the Power of Immunotherapy to More Patients
- [H2] “30 years ago, we envisioned a future where the immune system could be harnessed to cure cancer. That vision remains our driving force today—science-led, patient-focused, and unwavering in our mission to transform outcomes.”
- [H2] In the News
- [H2] Get answers about clinical trials, patient access, and more
- [H2] By the Numbers
- [H3] OncoDaily
- [H3] Avoiding Chemo: Two Promising Drugs Go Head-to-Head in New Clinical Trial
- [H3] Teaching the Immune System to Remember: Exclusive Conversation with Dr. Nicholas DeVito
- [H3] Balstilimab Plus Botensilimab Shows Better Response in MSS mCRC
- [H3] Neoadjuvant Botensilimab Plus Balstilimab Yields High MPR Rates in CRC
- [H3] Neoadjuvant Botensilimab Combo Elicits High MPR Rates in MSS/MSI-H CRC
- [H3] Combination Slows Metastatic CRC Progression Better Than Single Immunotherapy
- [H3] Botensilimab Plus Balstilimab Elicits Encouraging Responses in MSS mCRC Without Liver Mets
- [H3] Redefining Cancer Care
- [H3] I never knew how close to this disease I would eventually become – Benny Johnson’s personal story with cancer
- [H3] Neoadjuvant Botensilimab/Balstilimab Is Active in Resectable Colon Cancer, Despite MMR Status
- [H3] Overcoming barriers to immunotherapy for microsatellite stable colorectal cancer
- [H3] New bowel cancer treatment that shrinks tumours branded 'game-changing' giving hope to thousands
- [H3] Immunotherapies break into cold colorectal cancers at ASCO
- [H3] Royalty deals on the rise as Ligand takes stake in Agenus' success
- [H3] Updated Phase 1 Data Support Further Research of Botensilimab/Balstilimab in Refractory MSS CRC
- [H3] Botensilimab Combo Elicits Sustained Responses in Colorectal Cancer
- [H3] New Drug Combo Shows Promising Results Against Early Stages Of Colorectal Cancer
- [H3] Botensilimab/Balstilimab Boosts Survival in Non-MSI-H Metastatic CRC
- [H3] Botensilimab/Balstilimab Yields Durable Responses in Non-MSI-H mCRC
- [H3] Botensilimab Plus Balstilimab Provides OS Benefit in Heavily Pretreated MSS mCRC
- [H3] New Strategies for Targeting CTLA-4 Emerge
- [H3] Immunotherapy in Metastatic Colorectal Cancer: More Than Just MSI-H?
- [H3] Activity of Botensilimab and Bastilimab in Advanced Ovarian Cancer
- [H3] Botensilimab/Balstilimab Combo Elicits Deep Responses in Platinum-Resistant/Refractory Ovarian Cancer
- [H3] New data give Agenus' combo drug another boost, this time in ovarian cancer
- [H3] Novel Immunotherapy Combination Shows Activity in Microsatellite-Stable Metastatic Colorectal Cancer
- [H3] Studies of novel therapeutic approaches highlighted during Colorectal Cancer Awareness Month at Dana-Farber
- [H3] Unpacking the Latest Research in Gastrointestinal Cancers
- [H3] Botensilimab and balstilimab in metastatic, pre-treated MSS-CRC
- [H3] Combination of Botensilimab and Balstilimab Shows Activity in Patients With Metastatic Microsatellite-Stable Colorectal Cancer
- [H3] Combo results may offer route back to approval for Agenus' unlucky cervical cancer drug
- [H3] Immunotherapy with two novel drugs shows activity in colorectal cancer
- [H3] Avoiding Chemo: Two Promising Drugs Go Head-to-Head in New Clinical Trial
- [H3] Teaching the Immune System to Remember: Exclusive Conversation with Dr. Nicholas DeVito
- [H3] Balstilimab Plus Botensilimab Shows Better Response in MSS mCRC
- [H3] Neoadjuvant Botensilimab Plus Balstilimab Yields High MPR Rates in CRC
- [H3] Combination Slows Metastatic CRC Progression Better Than Single Immunotherapy
- [H3] Neoadjuvant Botensilimab Combo Elicits High MPR Rates in MSS/MSI-H CRC
- [H3] Botensilimab Plus Balstilimab Elicits Encouraging Responses in MSS mCRC Without Liver Mets
- [H3] Redefining Cancer Care
- [H3] I never knew how close to this disease I would eventually become – Benny Johnson’s personal story with cancer
- [H3] Neoadjuvant Botensilimab/Balstilimab Is Active in Resectable Colon Cancer, Despite MMR Status
- [H3] Overcoming barriers to immunotherapy for microsatellite stable colorectal cancer
- [H3] New bowel cancer treatment that shrinks tumours branded 'game-changing' giving hope to thousands
- [H3] Immunotherapies break into cold colorectal cancers at ASCO
- [H3] Royalty deals on the rise as Ligand takes stake in Agenus' success
- [H3] Updated Phase 1 Data Support Further Research of Botensilimab/Balstilimab in Refractory MSS CRC
- [H3] Botensilimab Combo Elicits Sustained Responses in Colorectal Cancer
- [H3] New Drug Combo Shows Promising Results Against Early Stages Of Colorectal Cancer
- [H3] Botensilimab/Balstilimab Boosts Survival in Non-MSI-H Metastatic CRC
- [H3] Botensilimab/Balstilimab Yields Durable Responses in Non-MSI-H mCRC
- [H3] Botensilimab Plus Balstilimab Provides OS Benefit in Heavily Pretreated MSS mCRC
- [H3] New Strategies for Targeting CTLA-4 Emerge
- [H3] Immunotherapy in Metastatic Colorectal Cancer: More Than Just MSI-H?
- [H3] Activity of Botensilimab and Bastilimab in Advanced Ovarian Cancer
- [H3] Botensilimab/Balstilimab Combo Elicits Deep Responses in Platinum-Resistant/Refractory Ovarian Cancer
- [H3] New data give Agenus' combo drug another boost, this time in ovarian cancer
- [H3] Novel Immunotherapy Combination Shows Activity in Microsatellite-Stable Metastatic Colorectal Cancer
- [H3] Studies of novel therapeutic approaches highlighted during Colorectal Cancer Awareness Month at Dana-Farber
- [H3] Unpacking the Latest Research in Gastrointestinal Cancers
- [H3] Botensilimab and balstilimab in metastatic, pre-treated MSS-CRC
- [H3] Combination of Botensilimab and Balstilimab Shows Activity in Patients With Metastatic Microsatellite-Stable Colorectal Cancer
- [H3] Combo results may offer route back to approval for Agenus' unlucky cervical cancer drug
- [H3] Immunotherapy with two novel drugs shows activity in colorectal cancer
Afbeeldingen
We vonden 164 afbeeldingen in de pagina.
164 alt attributen ontbreken. Voeg alternatieve text toe zodat zoekmachines beter kunnen beoordelen wat het onderwerp van de afbeeldingen is.
Text/HTML Ratio
Ratio : 5%
De ratio van text tot HTML code is below 15 procent, dit betekent dat uw pagina waarschijnlijk meer tekst nodig heeft.
Flash
Perfect, geen Flash content gevonden in uw website.
Iframe
Jammer, u heeft Iframes in uw website, dit betekent dat deze content niet kan worden geïndexeerd.
SEO Links
Herschreven URL
Perfect. Uw links zien er vriendelijk uit!
Underscores in de URLs
Perfect! Geen underscores gevonden in uw URLs.
In-page links
We vonden een totaal van 41 links inclusie 0 link(s) naar bestanden
| Ankertekst | Type | samenstelling |
|---|---|---|
| - | Intern | doFollow |
| - | Extern | doFollow |
| - | Extern | doFollow |
| - | Extern | doFollow |
| - | Extern | doFollow |
| - | Extern | doFollow |
| - | Extern | doFollow |
| - | Extern | doFollow |
| - | Extern | doFollow |
| - | Extern | doFollow |
| - | Extern | doFollow |
| - | Extern | doFollow |
| - | Extern | doFollow |
| - | Extern | doFollow |
| - | Extern | doFollow |
| - | Extern | doFollow |
| - | Extern | doFollow |
| - | Extern | doFollow |
| - | Extern | doFollow |
| - | Extern | doFollow |
| - | Extern | doFollow |
| - | Extern | doFollow |
| - | Extern | doFollow |
| - | Extern | doFollow |
| - | Extern | doFollow |
| - | Extern | doFollow |
| - | Extern | doFollow |
| - | Extern | doFollow |
| - | Extern | doFollow |
| - | Extern | doFollow |
| - | Extern | doFollow |
| - | Extern | doFollow |
| - | Extern | doFollow |
| - | Extern | doFollow |
| Opt-out preferences | Intern | doFollow |
| Terms and Conditions of Use | Intern | doFollow |
| Privacy Policy | Intern | doFollow |
| Community Guidelines | Intern | doFollow |
| Access to Investigational Medicines Policy | Intern | doFollow |
| Report Adverse Event | Intern | doFollow |
| Investor Portal | Intern | doFollow |
SEO Keywords
Keywords Cloud
immunotherapy news colorectal botensilimab january patient agenus access cancer balstilimab
Keywords Consistentie
| Keyword | Content | Title | Keywords | Description | Headings |
|---|---|---|---|---|---|
| cancer | 48 |  |
|
 |
|
| access | 29 | |
|
|
|
| botensilimab | 28 | |
|
|
|
| agenus | 25 | |
|
|
|
| colorectal | 23 | |
|
|
|
Bruikbaarheid
Url
Domein : agenusbio.com
Lengte : 13
Favicon
Goed, uw website heeft een favicon.
Printbaarheid
Jammer. We vonden geen Print-Vriendelijke CSS.
Taal
Goed. Uw ingestelde taal is en.
Dublin Core
Deze pagina maakt geen gebruik van Dublin Core.
Document
Doctype
HTML 5
Encoding
Perfect. Uw ingestelde Charset is UTF-8.
W3C Validiteit
Fouten : 0
Waarschuwingen : 0
E-mail Privacy
Waarschuwing! Er is op zijn minst 1 e-mailadres gevonden als platte tekst. (voorkom spam!). Gebruik deze gratis antispam protector om e-mailadressen te verbergen voor spammers.
Niet ondersteunde HTML
Geweldig! We hebben geen niet meer ondersteunde HTMl tags gevonden in uw HTML.
Speed Tips
|
Geweldig, uw website heeft geen tabellen in een tabel. |
|
Jammer, uw website maakt gebruik van inline styles. |
|
Geweldig, uw website heeft een correct aantal CSS bestanden. |
|
Jammer, uw website heeft teveel JS bestanden (meer dan 6). |
|
Perfect, uw website haalt voordeel uit gzip. |
Mobile
Mobile Optimization
|
Apple Icon |
|
Meta Viewport Tag |
|
Flash content |
Optimalisatie
XML Sitemap
Geweldig, uw website heeft een XML sitemap.
| https://www.agenusbio.com/sitemap.xml |
Robots.txt
https://agenusbio.com/robots.txt
Geweldig uw website heeft een robots.txt bestand.
Analytics
Ontbrekend
We hadden niet op te sporen van een analytics tool op deze website geplaatst.
Web Analytics laat u toe de bezoekersactiviteit op uw website te meten. U zou minstens 1 Analytics tool geïnstalleerd moeten hebben en een extra tool voor de bevestiging van de resultaten.
PageSpeed Insights
Device
Categorieën
Free SEO Testing Tool
Website review is een gratis tool waarmee u eenvoudig uw website kunt analyseren